Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

About this update from Sichuan Kelun Pharmaceutical Co., Ltd. Class A

[{"type":"text","content":"CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in previously treated locally advanced or metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2 -negative (HER2-) breast cancer (BC) was presented as an oral report by Professor Man Li from the Second Affiliated Hospital of Dalian Medical University (Presentation # LBA23, Proffered paper session 1: Breast cancer, metastatic). Previously, the new indication applications for sac-TMT for this indication was accepted by the National Medical Products Administration (NMPA) and was included in the priority review and approval process.","length":996,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":217,"url":"https://media.zenfs.com/en/prnewswire.com/079f86297f9f6ba19e597ea8264c916c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/fV7i71oU_t4mlt_mjlyGrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM4MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/079f86297f9f6ba19e597ea8264c916c","width":400,"height":217}},"href":"https://mma.prnewswire.com/media/2799758/image_1.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In the OptiTROP-Breast02 study, a total of 399 patients with HR+/HER2- BC who had progression on CDK4/6 inhibitors and received at least one prior line of chemotherapy in the advanced/metastatic setting were randomized (1:1) to receive sac-TMT or investigator's choice of chemotherapy (ICC).","length":295,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":225,"url":"https:...

More updates from Sichuan Kelun Pharmaceutical Co., Ltd. Class A